Editorials
GLP-1 based agents and acute pancreatitis
BMJ 2013; 346 doi: https://doi.org/10.1136/bmj.f1263 (Published 27 February 2013) Cite this as: BMJ 2013;346:f1263
Related articles
- News Published: 27 February 2013; BMJ 346 doi:10.1136/bmj.f1304
- News Published: 19 March 2013; BMJ 346 doi:10.1136/bmj.f1808
- Letter Published: 04 June 2013; BMJ 346 doi:10.1136/bmj.f3568
- Editorial Published: 10 June 2013; BMJ 346 doi:10.1136/bmj.f3692
- Editorial Published: 10 June 2013; BMJ 346 doi:10.1136/bmj.f3617
See more
- Cholera: Malawi is in grip of its deadliest outbreakBMJ February 09, 2023, 380 p328; DOI: https://doi.org/10.1136/bmj.p328
- Emergency care is in “dire” situation after loss of NHS beds, says royal collegeBMJ May 31, 2022, 377 o1376; DOI: https://doi.org/10.1136/bmj.o1376
- GP efforts to cut antibiotic use failed to curb spread of drug resistant E coli, evaluation findsBMJ August 05, 2021, 374 n1953; DOI: https://doi.org/10.1136/bmj.n1953
- Check covid status when planning emergency bowel surgery, doctors are toldBMJ March 11, 2021, 372 n695; DOI: https://doi.org/10.1136/bmj.n695
- Capsule endoscopies will be trialled in EnglandBMJ March 11, 2021, 372 n692; DOI: https://doi.org/10.1136/bmj.n692
Cited by...
- Incretin-Based Therapies and the Short-term Risk of Pancreatic Cancer: Results From Two Retrospective Cohort Studies
- Pancreatic Safety of Newer Incretin-Based Therapies: Are the "-tides" Finally Turning?
- Hope and fear for new classes of type 2 diabetes drugs: is there preclinical evidence that incretin-based therapies alter pancreatic morphology?
- Incretin therapy: should adverse consequences have been anticipated?
- Helping patients make sense of the risks of taking GLP-1 agonists
- Where is the evidence based on hard endpoints for the safety and effectiveness of sitagliptin in type 2 diabetes?
- FDA is to assess data linking type 2 diabetes drugs with pancreatitis